Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 6INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Lung Neoplasms 2Small Cell Lung Carcinoma 1

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Has results × amrubicin × Clear all
NCT05740566 2026-01-05

DeLLphi-304

Amgen

Phase 3 Active not recruiting
509 enrolled 11 charts 1 FDA
Thoracic

Small Cell Lung Carcinoma

NCT02481830 2023-07-27

CheckMate331

Bristol-Myers Squibb

Phase 3 Completed
569 enrolled 13 charts
Thoracic

Lung Neoplasms

NCT00660504 2014-07-18

Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer

Sumitomo Pharma (Suzhou) Co., Ltd.

Phase 3 Completed
300 enrolled 10 charts
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡